SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about completion of inspection

20 Sep 2023 Evaluate

 Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected the Unit IV, a Formulation manufacturing facility, of APL Healthcare, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023. At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature. The company will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest. 

The above information is a part of company’s filings submitted to BSE.


Aurobindo Pharma Share Price

1380.90 -4.75 (-0.34%)
20-Apr-2026 09:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.45
Dr. Reddys Lab 1234.80
Cipla 1241.25
Zydus Lifesciences 948.10
Lupin 2332.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×